Tracers / [177Lu]Lu-DOTA-ABDC2
[177Lu]Lu-DOTA-ABDC2
Also written as [Lu-177]Lu-DOTA-ABDC2
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Nanobody-derived albumin-binding domain fusion conjugated to DOTA chelator (CD47-targeting nanobody-ABD fusion)
- Target / mechanism
- CD47 PMID 36939440
- Clinical application
- CD47-targeted radioimmunotherapy of solid tumors PMID 36939440
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 62.76% (n = 1) no | 72% at 72 h in PBS | DOTA-ABDC2 | 36939440 2023 Research (Wash D C) The detailed methods for chelator conjugation, 68Ga/89Zr/177Lu-labeling, and quality control of the tracers are provided in the supplemental file. — The nondecay corrected radiolabeling yield of [177Lu]Lu-DOTA-C2 and [177Lu]Lu-DOTA-ABDC2 was 35.41% (n = 1) and 62.76% (n = 1), respectively. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-ABDC2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36939440. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36939440: 'DOTA-ABDC2'.